Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 12/20 | 0.49 |
| ▸ | NTRK2 | Q16620 | 12/20 | 0.49 |
| ▸ | IGF1R | P08069 | 4/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.49 |
| ▸ | NTRK3 | Q16288 | 9/20 | 0.40 |
| ▸ | BRAF | P15056 | 4/20 | 0.35 |
| ▸ | BCAT2 | O15382 | 2/20 | 0.33 |
| ▸ | BCAT1 | P54687 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Toltrazuril SCHEMBL29509205 | 0.92 | NTRK1 (0.57) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| Toltrazuril SCHEMBL248912 | 0.92 | NTRK1 (0.57) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| Toltrazuril SCHEMBL21812043 | 0.92 | NTRK1 (0.57) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL13780159 | 0.84 | NTRK1 (0.48) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL10975351 | 0.83 | NTRK1 (0.52) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL20328512 | 0.81 | NTRK1 (0.76) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL10525684 | 0.81 | NTRK1 (0.58) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL11478539 | 0.81 | NTRK1 (0.45) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL15783169 | 0.81 | NTRK1 (0.55) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL10525747 | 0.79 | NTRK1 (0.51) | NTRK1NTRK2IGF1RFGFR1NTRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802906-B1 | Process for the preparation of toltrazuril and an intermediate useful for its preparation | ERREGIERRE S.P.A. (IT) | 2017-10-31 | — | — | US | disclosed |
| US-20170291880-A1 | PROCESS FOR THE PREPARATION OF TOLTRAZURIL AND AN INTERMEDIATE USEFUL FOR ITS PREPARATION | ERREGIERRE S.P.A. (IT) | 2017-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291880-A1 | PROCESS FOR THE PREPARATION OF TOLTRAZURIL AND AN INTERMEDIATE USEFUL FOR ITS PREPARATION | TPMT, TTR, TFPI | NTRK1 36/4885NTRK2 476/4885IGF1R 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.